<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27206612</article-id><article-id pub-id-type="pmc">4875665</article-id><article-id pub-id-type="publisher-id">1375</article-id><article-id pub-id-type="doi">10.1186/s13063-016-1375-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Effectiveness of electroacupuncture for polycystic ovary syndrome: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jiao</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Feng</surname><given-names>Shuwei</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Zeng</surname><given-names>Jiuzhi</given-names></name><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xi</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Mingxiao</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Tang</surname><given-names>Hongzhi</given-names></name><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Fan</surname><given-names>Huaying</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Yang</surname><given-names>Jie</given-names></name><address><email>jenny_yang_jie@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Liang</surname><given-names>Fanrong</given-names></name><address><email>acuresearch@126.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><label/>Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan China </aff><aff id="Aff2"><label/>Maternal and Child Health Hospital of Sichuan Province, Chengdu, Sichuan China </aff><aff id="Aff3"><label/>Sichuan Orthopedic Hospital, Chengdu, Sichuan China </aff></contrib-group><pub-date pub-type="epub"><day>21</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>17</volume><elocation-id>256</elocation-id><history><date date-type="received"><day>10</day><month>12</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Chen et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>Whether electroacupuncture is effective for patients with polycystic ovary syndrome is still inconclusive. Therefore, this study aims to evaluate the add-on effects of electroacupuncture to conventional drugs for the treatment of polycystic ovary syndrome.</p></sec><sec><title>Methods/design</title><p>This study is a two-center, open-labeled, randomized, controlled trial. A total of 116 eligible patients with polycystic ovary syndrome will be randomly allocated in a 1:1 ratio to the electroacupuncture plus clomiphene citrate group or to the clomiphene citrate group. Participants in the electroacupuncture plus clomiphene citrate group will receive electroacupuncture treatment in addition to clomiphene citrate capsules, whereas participants in the clomiphene citrate group will be prescribed clomiphene citrate capsules only. Electroacupuncture treatment will be performed from the fifth day of menstruation or withdrawal bleeding until the next menstruation, in three sessions per week for three menstrual cycles. The primary outcome is the ovulation rate. The secondary outcomes include the dominant follicle rate, mean number of dominant follicles, endometrial thickness, time point of ovulation, follicular size before ovulation, luteinizing hormone, estradiol level, and pregnancy rate. The measuring points for outcomes will be baseline and the completion of treatment. Any adverse events occurring during the trial process will be recorded. In addition, a quality-monitoring group independent from the research team will be set up to control the quality of the trial.</p></sec><sec><title>Discussion</title><p>The design and methodological rigor of this trial will allow for the collection of valuable data to evaluate the effectiveness of electroacupuncture for treating polycystic ovary syndrome. Therefore, this trial will contribute reliable evidence for use in clinical decision-making in acupuncture therapy of polycystic ovary syndrome as well as to future research in acupuncture for polycystic ovary syndrome.</p></sec><sec><title>Trial registration</title><p>Chinese Clinical Trial Registry, <ext-link ext-link-type="uri" xlink:href="http://www.chictr.org.cn/showproj.aspx?proj=12273">ChiCTR-IOR-15007358</ext-link>, registered on 26 October 2015</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Electroacupuncture</kwd><kwd>Polycystic ovary syndrome</kwd><kwd>Effectiveness</kwd><kwd>RCT</kwd><kwd>Study protocol</kwd></kwd-group><funding-group><award-group><funding-source><institution>Science and Technology Department of Sichuan Province</institution></funding-source><award-id>2015SZ0096</award-id><principal-award-recipient><name><surname>Chen</surname><given-names>Jiao</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p>Polycystic ovary syndrome (PCOS), resulting from an imbalance of hormones, is a common disease in women. Its clinical manifestations vary, but include reproductive symptoms (hirsutism [<xref ref-type="bibr" rid="CR1">1</xref>], infertility [<xref ref-type="bibr" rid="CR2">2</xref>], pregnancy implications, and neonatal complications [<xref ref-type="bibr" rid="CR3">3</xref>]) and metabolic complications (obesity [<xref ref-type="bibr" rid="CR4">4</xref>], impaired glucose tolerance, metabolic syndrome [<xref ref-type="bibr" rid="CR5">5</xref>], and type 2 diabetes mellitus [<xref ref-type="bibr" rid="CR6">6</xref>]). Usually, many psychological comorbidities accompany PCOS, including depression, anxiety, moodiness, panic attacks, body dissatisfaction, eating disorders, and a lower health-related quality of life [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. As one of the common causes of anovulatory infertility, PCOS accounts for a significant proportion (40&#x000a0;%) of all women who receive infertility treatment [<xref ref-type="bibr" rid="CR2">2</xref>]. More than 116 million (3.42&#x000a0;%) women worldwide are affected by PCOS [<xref ref-type="bibr" rid="CR9">9</xref>]. Using the Rotterdam criteria, the prevalence has been as high as 17.8&#x02009;&#x000b1;&#x02009;2.8&#x000a0;% [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p>Currently, first-line conventional therapy for infertile women with PCOS is the oral administration of antiestrogen agents (for example, clomiphene citrate). Nevertheless, from a clinical point of view, the current management of PCOS with these drugs is not always satisfactory and produces some obvious side effects. After taking clomiphene citrate, metformin, or both, 41&#x000a0;%, 76.3&#x000a0;%, and 31.6&#x000a0;% of women, respectively, still failed to ovulate [<xref ref-type="bibr" rid="CR11">11</xref>]. The live-birth rate for these patients was only 22.5&#x000a0;% after taking clomiphene citrate, 7.2&#x000a0;% after taking metformin, and 26.8&#x000a0;% after taking both clomiphene citrate and metformin. Among pregnancies, clomiphene citrate caused multiple pregnancies in 6.0&#x000a0;% of the cases. Other side effects include gastrointestinal symptoms, hot flashes, and symptoms associated with ovarian enlargement and ovulation [<xref ref-type="bibr" rid="CR12">12</xref>].</p><p>Whereas first-line conventional therapy is not satisfactory, acupuncture, as a nonpharmacological therapy, is gaining popularity. Findings from previous clinical trials suggest acupuncture may induce ovulation [<xref ref-type="bibr" rid="CR13">13</xref>]; improve menstrual frequency [<xref ref-type="bibr" rid="CR14">14</xref>]; and improve depression, anxiety, and health-related quality of life [<xref ref-type="bibr" rid="CR15">15</xref>] in PCOS patients. Some of the mechanisms underlying acupuncture as a treatment for PCOS have been identified. Acupuncture is able to decrease abnormally high levels of circulating luteinizing hormone (LH), which affect the LH/follicle-stimulating hormone (FSH) ratio [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], and high levels of testosterone [<xref ref-type="bibr" rid="CR17">17</xref>]. Additionally, the low associated adverse-events rate, a low risk of multiple pregnancies, and the low cost of acupuncture have been noted [<xref ref-type="bibr" rid="CR18">18</xref>]. However, the methodological quality of these clinical trials varies, resulting in inconclusive statements on the effectiveness of acupuncture for PCOS. In this case, we designed this two-center, open-labeled, randomized controlled trial (RCT) to evaluate the add-on effects of electroacupuncture to conventional drugs on ovulation and some sex hormones in women with PCOS.</p></sec><sec id="Sec2"><title>Methods/design</title><sec id="Sec3"><title>Overview of the study design</title><p>We designed an open-labeled RCT. The interventions will be performed under ideal circumstances. Therefore, this trial will be carried out in academic settings: the First Affiliated Hospital of Chengdu University of Traditional Chinese Medicine and the Third Affiliated Hospital of Chengdu University of Traditional Chinese Medicine.&#x000a0;The flow is shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>Flow chart of the trial</p></caption><graphic xlink:href="13063_2016_1375_Fig1_HTML" id="MO1"/></fig></p><p>Before inclusion, participants will be screened in the aforementioned research centers. If the participants meet the inclusion criteria and agree to participate, they will be asked to sign the informed consent form and, then, will be randomized into the electroacupuncture plus clomiphene citrate group (EA group) or the clomiphene citrate group (CC group).</p><p>After randomization, the participants will go through a total treatment period of three menstrual cycles. Outcome measurements will be assessed by assessors, blinded to the group assignment, at baseline and the end of treatment. Adverse events will be recorded for the assessment of safety. In addition, a quality monitoring board will be set up to control the quality of the protocol implementation.</p><p>The study protocol has been reviewed and approved by local institutional review boards and ethics committees. It follows the principles of the CONSORT and STRICTA statements as well as the Declaration of Helsinki (Sixth revision, 2008). Informed consent will be obtained from all participants.</p></sec><sec id="Sec4"><title>Ethics approval</title><p>All trial procedures place the participant&#x02019;s benefit as the highest priority. The present study protocol has already been ethically approved by the Sichuan Regional Ethics Review Committee on Traditional Chinese Medicine with the ethical approval identifier 2015KL-009.</p></sec><sec id="Sec5"><title>Participants</title><p>We plan to recruit patients with PCOS diagnosed on the basis of <italic>Revised 2003 Consensus on Diagnostic Criteria and Long-Term Health Risks Related to Polycystic Ovary Syndrome</italic> established by The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group [<xref ref-type="bibr" rid="CR19">19</xref>]. According to these criteria, women with two out of three of the following items can be diagnosed as having PCOS: (1) oligoovulation or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, and (3) polycystic ovaries and exclusion of other etiologies (congenital adrenal hyperplasia, androgen-secreting tumors, Cushing&#x02019;s syndrome). Further assessment of eligibility is based on the inclusion and exclusion criterion as follows.</p><sec id="Sec6"><title>Inclusion criteria</title><p><list list-type="order"><list-item><p>Female, age 20 to 40&#x000a0;years</p></list-item><list-item><p>Diagnosed as having PCOS</p></list-item><list-item><p>Sign the inform consent</p></list-item></list></p></sec><sec id="Sec7"><title>Exclusion criteria</title><p><list list-type="order"><list-item><p>Allergic constitution or allergic to various kinds of medicine</p></list-item><list-item><p>Hyperandrogenism due to other reasons, including hyperprolactinemia, thyroid disease, congenital adrenal hyperplasia, Cushing&#x02019;s syndrome, etc.</p></list-item><list-item><p>Pathological endometrial changes, such as uterine malformation, hysteromyoma, etc., diagnosed by B ultrasound</p></list-item><list-item><p>Genital tract malformation, gonadal dysgenesis, fallopian tube block, etc.</p></list-item><list-item><p>Severe heart, liver, or renal dysfunction or hematological, respiratory, cardiovascular, psychiatric, or other metabolic diseases</p></list-item><list-item><p>Within 6&#x000a0;weeks post-abortion</p></list-item><list-item><p>Use of hormonal or other medication including Chinese herbal prescriptions in the past 3&#x000a0;months</p></list-item><list-item><p>Participation in other clinical trials at the same time</p></list-item></list></p></sec></sec><sec id="Sec8"><title>Randomization</title><p>In this trial, participants will be randomly assigned to either the EA group or the CC group in a 1:1 ratio using a table of random numbers. The random numbers are generated using SAS statistical software package (Version 9.1, SAS Institute Inc.).</p></sec><sec id="Sec9"><title>Blinding</title><p>This is an open-labeled trial; therefore, neither the patients nor the clinical practitioners will be blinded for the entire process. However, in order to eliminate potential bias, other researchers, including data collectors and statisticians, will be blinded.</p></sec><sec id="Sec10"><title>Interventions</title><p>Participants in the EA group will receive electroacupuncture treatment in addition to the oral administration of clomiphene citrate, whereas participants in the CC group will receive clomiphene citrate only. Treatment in both group will last three menstrual cycles. The intervention in this trial involves a rigorous acupuncture schedule. To ensure the compliance of acupuncturists to the schedule, we ask them to take pretrial training and an entrance exam for this trial. All included acupuncturists will have at least 2&#x000a0;years of practical experience in clinical acupuncture.</p><sec id="Sec11"><title>Clomiphene citrate therapy</title><p>On the fifth day of menstruation, all participants, except for those with amenorrhea, will receive a pharmacological treatment regimen of 50&#x000a0;mg clomiphene citrate, taken once each day for 5 continuous days. Patients with amenorrhea will receive the same pharmacological treatment regimen after withdrawal bleeding has been induced by taking progestin. In cases of no ovulation, an additional 50&#x000a0;mg will be added to the dose in the next menstrual cycle. The maximum dose will not exceed 150&#x000a0;mg. The therapy will last for three menstrual cycles.</p></sec><sec id="Sec12"><title>Electroacupuncture</title><p>In order to increase the reproducibility and internal validity of the trial, electroacupuncture treatment will be applied to PCOS patients. As the stimulation of electroacupuncture can be more quantifiable relative to manual acupuncture, its employment may reduce the risk of bias somewhat. Sanyinjiao (SP 6), Guanyuan (BL 26) Zhongji (CV 3), and Zigong (EX-CA 1) have been chosen for the formula of compulsory acupoints. Additionally, sets of three arbitrary points will be alternately selected according to the phase of the menstrual cycle: Taichong (LR 3) and Taixi (KI 3) will be needled after menstruation; Mingmen (GV 4) and Xuehai (SP 10), during the ovulatory period; and Xuehai (SP 10) and Geshu (BL 17), before the next menstruation.</p><p>Each acupoint will be needled using a filiform needle (25&#x02013;50&#x000a0;mm in length and 0.25&#x000a0;mm in diameter) to achieve a <italic>Deqi</italic> sensation (refers to a sensation of numbness, distension, or electrical tingling at the needling site and might radiate along the corresponding meridian). Then, an auxiliary needle (13&#x000a0;mm in length and 0.18&#x000a0;mm in diameter) will be inserted, 2&#x000a0;mm lateral to the first needle, to a depth of 2&#x000a0;mm without achieving <italic>Deqi</italic>. Electrical stimulation will be applied at every acupoint, with one electrode connected to the filiform needle and the other to the auxiliary needle. This method circumscribes the electrical stimulation nearby, rather than going across the human body surface to cause performance bias. Electrical stimulation will last for 30&#x000a0;min in each acupuncture session. Electroacupuncture treatment will be performed three times per week from the fifth day of menstruation or withdrawal bleeding until before the next menstruation for three menstrual cycles.</p></sec></sec><sec id="Sec13"><title>Outcome measurements</title><sec id="Sec14"><title>Primary outcome</title><p>The primary outcome will be the ovulation rate.</p></sec><sec id="Sec15"><title>Secondary outcomes</title><p>The secondary outcomes will include the dominant follicle rate, mean number of dominant follicles, endometrial thickness, time point of ovulation, follicular size before ovulation, luteinizing hormone (LH) level, estradiol (E2) level, and pregnancy rate.</p></sec><sec id="Sec16"><title>Time points of outcome measurement</title><p>Outcomes will be assessed at two time points: baseline and the completion of the treatment. Furthermore, patients will be given some regular tests at baseline, including routine blood tests, liver function test, and kidney function test. The overview of the outcome measurement at the different time points is shown in Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Trial process chart</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Time point</th><th>Baseline</th><th>Post-treatment</th></tr></thead><tbody><tr><td colspan="3">Diagnosis</td></tr><tr><td>&#x02003;Inclusion confirmed</td><td>&#x02713;</td><td/></tr><tr><td>&#x02003;Informed consent signed</td><td>&#x02713;</td><td/></tr><tr><td>&#x02003;Body sign</td><td>&#x02713;</td><td>&#x02713;</td></tr><tr><td>&#x02003;Disease history</td><td>&#x02713;</td><td/></tr><tr><td>&#x02003;Treatment history</td><td>&#x02713;</td><td/></tr><tr><td>&#x02003;Comorbidity</td><td>&#x02713;</td><td>&#x02713;</td></tr><tr><td>&#x02003;Current treatment</td><td>&#x02713;</td><td>&#x02713;</td></tr><tr><td colspan="3">Outcome assessment</td></tr><tr><td>&#x02003;B ultrasound</td><td>&#x02713;</td><td>&#x02713;</td></tr><tr><td>&#x02003;Follicle-stimulating hormone</td><td>&#x02713;</td><td>&#x02713;</td></tr><tr><td>&#x02003;Luteinizing hormone</td><td>&#x02713;</td><td>&#x02713;</td></tr><tr><td>&#x02003;Testosterone</td><td>&#x02713;</td><td>&#x02713;</td></tr><tr><td>&#x02003;Estradiol</td><td>&#x02713;</td><td>&#x02713;</td></tr><tr><td>&#x02003;Blood HCG</td><td>&#x02713;</td><td>&#x02713;</td></tr><tr><td colspan="3">Regular tests</td></tr><tr><td>&#x02003;Routine blood tests</td><td>&#x02713;</td><td/></tr><tr><td>&#x02003;Liver function test</td><td>&#x02713;</td><td/></tr><tr><td>&#x02003;Kidney function test</td><td>&#x02713;</td><td/></tr><tr><td colspan="3">Data collection and statistical analysis</td></tr><tr><td>&#x02003;Adverse event</td><td/><td>&#x02713;</td></tr><tr><td>&#x02003;Causes of dropout</td><td/><td>&#x02713;</td></tr><tr><td>&#x02003;Safety analysis</td><td/><td>&#x02713;</td></tr><tr><td>&#x02003;Compliance analysis</td><td/><td>&#x02713;</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec17"><title>Assessment of adverse events</title><p>According to previous RCTs, acupuncture may cause several types of adverse events, including subcutaneous hematoma, bleeding, skin bruising, and needle site pain. Among these adverse events, subcutaneous hematoma and bleeding were the most common [<xref ref-type="bibr" rid="CR20">20</xref>]. Acupuncture-related adverse events, including bleeding, hematoma, fainting, serious pain, local infection, etc., will be carefully recorded in the case report forms.</p></sec><sec id="Sec18"><title>Sample size calculation</title><p>A previous study indicated that 59&#x000a0;% of women with PCOS ovulated after receiving clomiphene citrate [<xref ref-type="bibr" rid="CR11">11</xref>]. In this trial, the ovulation rate is expected to be 75&#x000a0;% in the EA group and 55&#x000a0;% in the CC group. Considering a significant level of 0.05 and a power of 0.80, 50 participants in each group are required, as calculated by <italic>t</italic> test in G*Power (Version 3, Institute for Experimental Psychology, Heinrich-Heine-University, Germany). At least 58 participants per group and 116 total participants will be recruited to allow for a 15&#x000a0;% dropout rate.</p></sec><sec id="Sec19"><title>Statistical analysis</title><p>A statistician blinded to the whole trial process will perform the statistical analyses using the SAS statistical software package (Version 9.1, SAS Institute Inc.) in the Computer Integrated Manufacturing System. For the evaluation of a curative effect in this trial, the full analysis set (FAS) will be used. The FAS is determined according to an intention-to-treat (ITT) population; all randomized patients who receive at least one treatment session will be included in the analysis set. The per-protocol analysis set (PPS) is defined as the patients who complete the study and do not have major protocol violations. Demographic data and other basic indicators will be analyzed to test the balance of the two groups at baseline. The main indicators and global indicators will be analyzed within the FAS and PPS. The results will be described with mean, standard deviation, median, P25 (percentile 25), P75 (percentile 75), maximum, and minimum values of the differences between the treatment period and the baseline period. Between-group differences will be tested using repeated measure analyses of the variance. The accepted level of significance for all analyses was <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05. Considering the influences of other factors on the effectiveness, such as age, duration of disease, etc., these factors will be considered as covariants for the covariance analysis or logistic regression analysis when comparisons are made between the groups. Missing data will be replaced according to the principle of multiple imputations.</p></sec><sec id="Sec20"><title>Quality monitoring</title><p>To control the trial&#x02019;s quality, an independent quality-monitoring group will be established. The project leader will be in charge of the whole quality monitoring, whereas supervisors will be in charge of the quality monitoring in each center. The whole process will be supervised. All data will be verified to ensure they are recorded and reported accurately, authentically, completely, and consistently with the original data.</p></sec></sec><sec id="Sec21"><title>Discussion</title><p>The present trial is a comparative study of the effectiveness of electroacupuncture on ovulation and some related sex hormones in patients with PCOS.</p><p>Due to the weakness of the methodological design, the overall quality of clinical trials concerning the effectiveness of acupuncture treatment for infertility in women with PCOS is relatively low [<xref ref-type="bibr" rid="CR18">18</xref>]. Although an ongoing multicenter RCT is underway, more RCTs that are properly designed are needed before drawing conclusions concerning the use of acupuncture in the management of PCOS [<xref ref-type="bibr" rid="CR21">21</xref>]. Therefore, this trial is designed as an RCT to evaluate the add-on effects of electroacupuncture to conventional drugs on PCOS in terms of promoting ovulation and regulating related hormones. This study has several strengths.</p><p>On one hand, this trial is designed as an RCT. Due to its ability to reduce spurious causality and bias, the RCT is the most reliable scientific evidence in the hierarchy of evidence and can influence healthcare policy and practice. The RCT, the gold standard in clinical trials, is often used to test the efficacy or effectiveness of various types of medical interventions and may provide information about adverse effects. Therefore, this rigorously designed RCT, which will evaluate the effectiveness of electroacupuncture on PCOS in terms of promoting ovulation and regulating related hormones, will be able to provide some reliable evidence regarding the use of acupuncture for PCOS.</p><p>On the other hand, the therapeutic principle of treatment based on the phase of the menstrual cycle will be followed in this trial. In traditional Chinese Medicine, treatment based on syndrome differentiation is an important therapeutic principle. In gynecological diseases, treatment based on the phase of the menstrual cycle is another important principle and can enhance therapeutic effects. Therefore, this principle will be followed in our study. Sanyinjiao (SP 6), Zigong (EX-CA 1), Guanyuan (BL 26), and Zhongji (CV 3) have been chosen as the compulsory acupoints. These four acupoints are the ones most frequently used to treat PCOS, according to a text-mining analysis [<xref ref-type="bibr" rid="CR22">22</xref>]. Sanyinjiao (SP 6) and Zigong (EX-CA 1) are important acupoints for the treatment of gynecological diseases in acupuncture practice. Guanyuan (BL 26) can reinforce kidney and warm Yang. Zhongji (CV 3) is located in the Conception Vessel and is used to regulate the Chong Vessel and Conception Vessel. In addition, according to a previous study [<xref ref-type="bibr" rid="CR23">23</xref>], three sets of arbitrary points will be alternately selected according to the phase of the menstrual cycle, with each group consisting of two acupoints. After menstruation, Taichong (LR 3) and Taixi (KI 3) will be punctured to regulate qi and nourish the liver and kidneys. During the ovulatory period, Mingmen (GV 4) and Xuehai (SP 10) will be punctured to tonify qi and regulate the blood to promote ovulation. Before the next menstruation, Xuehai (SP 10) and Geshu (BL 17) will be punctured to regulate the blood.</p><p>This rigorously designed trial will allow for the collection of valuable and reliable data to evaluate the effectiveness of a specific acupuncture protocol for treating PCOS. This study will contribute to the clinical evidence regarding the effectiveness of electroacupuncture for women with PCOS.</p></sec><sec id="Sec22"><title>Trial status</title><p>The trial had not yet begun at the time of manuscript submission.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>PCOS</term><def><p>polycystic ovary syndrome</p></def></def-item><def-item><term>EA</term><def><p>electroacupuncture</p></def></def-item><def-item><term>CC</term><def><p>clomiphene citrate</p></def></def-item><def-item><term>LH</term><def><p>luteinizing hormone</p></def></def-item><def-item><term>E2</term><def><p>estradiol</p></def></def-item><def-item><term>FSH</term><def><p>follicle-stimulating hormone</p></def></def-item><def-item><term>RCT</term><def><p>randomized controlled trial</p></def></def-item><def-item><term>CONSORT</term><def><p>Consolidated Standards of Reporting Trials</p></def></def-item><def-item><term>STRICTA</term><def><p>Standards for Reporting Interventions in Controlled Trials of Acupuncture</p></def></def-item><def-item><term>ESHRE</term><def><p>European Society of Human Reproduction and Embryology</p></def></def-item><def-item><term>ASRM</term><def><p>American Society for Reproductive Medicine</p></def></def-item><def-item><term>SAS</term><def><p>Statistical Analysis System</p></def></def-item><def-item><term>FAS</term><def><p>full analysis set</p></def></def-item><def-item><term>ITT</term><def><p>intention-to-treat</p></def></def-item><def-item><term>PPS</term><def><p>per-protocol analysis set</p></def></def-item><def-item><term>P25</term><def><p>percentile 25</p></def></def-item><def-item><term>P75</term><def><p>percentile 75</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>JC and SWF contributed equally to the manuscript. JC conceived the study, participated in its design, and drafted the manuscript. SWF participated in the design and drafted the manuscript. JZZ, XW, MXY, HZT, and HYF participated in the design and helped to draft the manuscript. JY and FRL conceived the study, participated in its design, and helped to draft the manuscript. All authors read and approved the final manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>This trial was financially supported by funds from the Science and Technology Department of Sichuan Province (grant number 2015SZ0096).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Escobar-Morreale</surname><given-names>HF</given-names></name><name><surname>Carmina</surname><given-names>E</given-names></name><name><surname>Dewailly</surname><given-names>D</given-names></name><name><surname>Gambineri</surname><given-names>A</given-names></name><name><surname>Kelestimur</surname><given-names>F</given-names></name><name><surname>Moghetti</surname><given-names>P</given-names></name><etal/></person-group><article-title>Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society</article-title><source>Hum Reprod Update</source><year>2012</year><volume>18</volume><issue>2</issue><fpage>146</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1093/humupd/dmr042</pub-id><pub-id pub-id-type="pmid">22064667</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joham</surname><given-names>AE</given-names></name><name><surname>Teede</surname><given-names>HJ</given-names></name><name><surname>Ranasinha</surname><given-names>S</given-names></name><name><surname>Zoungas</surname><given-names>S</given-names></name><name><surname>Boyle</surname><given-names>J</given-names></name></person-group><article-title>Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study</article-title><source>J Womens Health</source><year>2015</year><volume>24</volume><issue>4</issue><fpage>299</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1089/jwh.2014.5000</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boomsma</surname><given-names>CM</given-names></name><name><surname>Eijkemans</surname><given-names>MJ</given-names></name><name><surname>Hughes</surname><given-names>EG</given-names></name><name><surname>Visser</surname><given-names>GH</given-names></name><name><surname>Fauser</surname><given-names>BC</given-names></name><name><surname>Macklon</surname><given-names>NS</given-names></name></person-group><article-title>A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome</article-title><source>Hum Reprod Update</source><year>2006</year><volume>12</volume><issue>6</issue><fpage>673</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/humupd/dml036</pub-id><pub-id pub-id-type="pmid">16891296</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moran</surname><given-names>L</given-names></name><name><surname>Teede</surname><given-names>H</given-names></name></person-group><article-title>Metabolic features of the reproductive phenotypes of polycystic ovary syndrome</article-title><source>Hum Reprod Update</source><year>2009</year><volume>15</volume><issue>4</issue><fpage>477</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1093/humupd/dmp008</pub-id><pub-id pub-id-type="pmid">19279045</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marcondes</surname><given-names>JA</given-names></name><name><surname>Hayashida</surname><given-names>SA</given-names></name><name><surname>Barcellos</surname><given-names>CR</given-names></name><name><surname>Rocha</surname><given-names>MP</given-names></name><name><surname>Maciel</surname><given-names>GA</given-names></name><name><surname>Baracat</surname><given-names>EC</given-names></name></person-group><article-title>Metabolic syndrome in women with polycystic ovary syndrome: prevalence, characteristics and predictors</article-title><source>Arq Bras Endocrinol Metabol</source><year>2007</year><volume>51</volume><issue>6</issue><fpage>972</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1590/S0004-27302007000600012</pub-id><pub-id pub-id-type="pmid">17934665</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legro</surname><given-names>RS</given-names></name><name><surname>Kunselman</surname><given-names>AR</given-names></name><name><surname>Dodson</surname><given-names>WC</given-names></name><name><surname>Dunaif</surname><given-names>A</given-names></name></person-group><article-title>Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women</article-title><source>J Clin Endocrinol Metab</source><year>1999</year><volume>84</volume><issue>1</issue><fpage>165</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">9920077</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>AA</given-names></name><name><surname>Gibson-Helm</surname><given-names>ME</given-names></name><name><surname>Teede</surname><given-names>HJ</given-names></name></person-group><article-title>Anxiety and depression in polycystic ovary syndrome: a comprehensive investigation</article-title><source>Fertil Steril</source><year>2010</year><volume>93</volume><issue>7</issue><fpage>2421</fpage><lpage>3</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2009.09.018</pub-id><pub-id pub-id-type="pmid">20117778</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himelein</surname><given-names>MJ</given-names></name><name><surname>Thatcher</surname><given-names>SS</given-names></name></person-group><article-title>Polycystic ovary syndrome and mental health: A review</article-title><source>Obstet Gynecol Surv</source><year>2006</year><volume>61</volume><issue>11</issue><fpage>723</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1097/01.ogx.0000243772.33357.84</pub-id><pub-id pub-id-type="pmid">17044949</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vos</surname><given-names>T</given-names></name><name><surname>Flaxman</surname><given-names>AD</given-names></name><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Lozano</surname><given-names>R</given-names></name><name><surname>Michaud</surname><given-names>C</given-names></name><name><surname>Ezzati</surname><given-names>M</given-names></name><etal/></person-group><article-title>Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010</article-title><source>Lancet</source><year>2012</year><volume>380</volume><issue>9859</issue><fpage>2163</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61729-2</pub-id><pub-id pub-id-type="pmid">23245607</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>March</surname><given-names>WA</given-names></name><name><surname>Moore</surname><given-names>VM</given-names></name><name><surname>Willson</surname><given-names>KJ</given-names></name><name><surname>Phillips</surname><given-names>DI</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name><name><surname>Davies</surname><given-names>MJ</given-names></name></person-group><article-title>The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria</article-title><source>Hum Reprod</source><year>2010</year><volume>25</volume><issue>2</issue><fpage>544</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1093/humrep/dep399</pub-id><pub-id pub-id-type="pmid">19910321</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zain</surname><given-names>MM</given-names></name><name><surname>Jamaluddin</surname><given-names>R</given-names></name><name><surname>Ibrahim</surname><given-names>A</given-names></name><name><surname>Norman</surname><given-names>RJ</given-names></name></person-group><article-title>Comparison of clomiphene citrate, metformin, or the combination of both for first-line ovulation induction, achievement of pregnancy, and live birth in Asian women with polycystic ovary syndrome: a randomized controlled trial</article-title><source>Fertil Steril</source><year>2009</year><volume>91</volume><issue>2</issue><fpage>514</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2007.12.002</pub-id><pub-id pub-id-type="pmid">18321486</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Legro</surname><given-names>RS</given-names></name><name><surname>Barnhart</surname><given-names>HX</given-names></name><name><surname>Schlaff</surname><given-names>WD</given-names></name><name><surname>Carr</surname><given-names>BR</given-names></name><name><surname>Diamond</surname><given-names>MP</given-names></name><name><surname>Carson</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome</article-title><source>N Engl J Med</source><year>2007</year><volume>356</volume><issue>6</issue><fpage>551</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa063971</pub-id><pub-id pub-id-type="pmid">17287476</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansson</surname><given-names>J</given-names></name><name><surname>Redman</surname><given-names>L</given-names></name><name><surname>Veldhuis</surname><given-names>PP</given-names></name><name><surname>Sazonova</surname><given-names>A</given-names></name><name><surname>Labrie</surname><given-names>F</given-names></name><name><surname>Holm</surname><given-names>G</given-names></name><etal/></person-group><article-title>Acupuncture for ovulation induction in polycystic ovary syndrome: a randomized controlled trial</article-title><source>Am J Physiol Endocrinol Metab</source><year>2013</year><volume>304</volume><issue>9</issue><fpage>E934</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00039.2013</pub-id><pub-id pub-id-type="pmid">23482444</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>YH</given-names></name><name><surname>Wang</surname><given-names>XH</given-names></name><name><surname>Lai</surname><given-names>MH</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>HX</given-names></name></person-group><article-title>Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial</article-title><source>J Altern Complement Med</source><year>2013</year><volume>19</volume><issue>9</issue><fpage>740</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1089/acm.2012.0429</pub-id><pub-id pub-id-type="pmid">23676106</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stener-Victorin</surname><given-names>E</given-names></name><name><surname>Holm</surname><given-names>G</given-names></name><name><surname>Janson</surname><given-names>PO</given-names></name><name><surname>Gustafson</surname><given-names>D</given-names></name><name><surname>Waern</surname><given-names>M</given-names></name></person-group><article-title>Acupuncture and physical exercise for affective symptoms and health-related quality of life in polycystic ovary syndrome: secondary analysis from a randomized controlled trial</article-title><source>BMC Complement Altern Med.</source><year>2013</year><volume>13</volume><fpage>131</fpage><pub-id pub-id-type="doi">10.1186/1472-6882-13-131</pub-id><pub-id pub-id-type="pmid">23763822</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maliqueo</surname><given-names>M</given-names></name><name><surname>Benrick</surname><given-names>A</given-names></name><name><surname>Alvi</surname><given-names>A</given-names></name><name><surname>Johansson</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Labrie</surname><given-names>F</given-names></name><etal/></person-group><article-title>Circulating gonadotropins and ovarian adiponectin system are modulated by acupuncture independently of sex steroid or beta-adrenergic action in a female hyperandrogenic rat model of polycystic ovary syndrome</article-title><source>Mol Cell Endocrinol.</source><year>2015</year><volume>412</volume><fpage>159</fpage><lpage>69</lpage><pub-id pub-id-type="doi">10.1016/j.mce.2015.04.026</pub-id><pub-id pub-id-type="pmid">25963796</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jedel</surname><given-names>E</given-names></name><name><surname>Labrie</surname><given-names>F</given-names></name><name><surname>Oden</surname><given-names>A</given-names></name><name><surname>Holm</surname><given-names>G</given-names></name><name><surname>Nilsson</surname><given-names>L</given-names></name><name><surname>Janson</surname><given-names>PO</given-names></name><etal/></person-group><article-title>Impact of electro-acupuncture and physical exercise on hyperandrogenism and oligo/amenorrhea in women with polycystic ovary syndrome: a randomized controlled trial</article-title><source>Am J Physiol Endocrinol Metab</source><year>2011</year><volume>300</volume><issue>1</issue><fpage>E37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1152/ajpendo.00495.2010</pub-id><pub-id pub-id-type="pmid">20943753</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>DC</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Cheng</surname><given-names>LN</given-names></name><name><surname>Xue</surname><given-names>CC</given-names></name><name><surname>Wong</surname><given-names>FW</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Acupuncture for polycystic ovarian syndrome</article-title><source>Cochrane Database Syst Rev.</source><year>2011</year><volume>8</volume><fpage>CD007689</fpage><pub-id pub-id-type="pmid">21833961</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Rotterdam EA-SPCWG</collab></person-group><article-title>Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome</article-title><source>Fertil Steril</source><year>2004</year><volume>81</volume><issue>1</issue><fpage>19</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2003.10.004</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>FW</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Cheng</surname><given-names>LH</given-names></name><etal/></person-group><article-title>Adverse events associated with acupuncture: three multicentre randomized controlled trials of 1968 cases in China</article-title><source>Trials.</source><year>2011</year><volume>12</volume><fpage>87</fpage><pub-id pub-id-type="doi">10.1186/1745-6215-12-87</pub-id><pub-id pub-id-type="pmid">21435214</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>Acupuncture and clomiphene citrate for live birth in polycystic ovary syndrome: study design of a randomized controlled trial</article-title><source>eCAM.</source><year>2013</year><volume>2013</volume><fpage>527303</fpage><pub-id pub-id-type="pmid">24023577</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>J</given-names></name></person-group><source>Acupoints analysis by data mining in polycystic ovary syndrome and its related symptom</source><year>2012</year><publisher-loc>Heilongjiang</publisher-loc><publisher-name>Heilongjiang University Of Chinese Medicine</publisher-name></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>K</given-names></name></person-group><source>Random controlled prospective study of the treatment for PCOS by acupuncture and Chinese medicine combined</source><year>2011</year><publisher-loc>Guangdong</publisher-loc><publisher-name>Guangzhou University of Chinese Medicine</publisher-name></element-citation></ref></ref-list></back></article>